Antitumor Activity of 3-Ingenyl Angelate: Plasma Membrane and Mitochondrial Disruption and Necrotic Cell Death

Cancer Research

Volumn 64, Issue 8, 2004, Pages 2833-2839

  Ogbourne, Steven M ^a   Suhrbier, Andreas ^a   Jones, Brad ^a   Cozzi, Sarah Jane ^a   Boyle, Glen M ^a   Morris, Melanie ^a   McAlpine, Devi ^a   Johns, Jenny ^a   Scott, Tania M ^a   Sutherland, Kirsty P ^a   Gardner, Joy M ^a   Le, Thuy T T ^a   Lenarczyk, Aleksandra ^a   Aylward, James H ^b   Parsons, Peter G ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Peplin Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 INGENYL ANGELATE; ANTINEOPLASTIC AGENT; CHROMIUM 51; DITERPENE; PEP 005; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CELL MEMBRANE; CONTROLLED STUDY; CRYOSURGERY; CURETTAGE; ELECTRON MICROSCOPY; ERYTHEMA; EUPHORBIA; EUPHORBIA PEPLUS; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MELANOMA; MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; DITERPENES; ESTERS; FEMALE; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MITOCHONDRIA; NEOPLASMS, EXPERIMENTAL;

EID: 12344290175     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2837     Document Type: Article

References (49)

1. American Cancer Society. Cancer Facts and Figures, 2003. Pamphlet. American Cancer Society; 2003.
2. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003;48:425-9.
3. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15:315-28.
4. Koplin L, Zarem HA. Recurrent basal cell carcinoma. A review concerning the incidence, behavior, and management of recurrent basal cell carcinoma, with emphasis on the incompletely excised lesion. Plast Reconstr Surg 1980;65: 656-64.
5. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135: 1177-83.
6. Rowe DE, Carroll RJ, Day CL, Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection J Am Acad Dermatol 1992;26: 976-90.
7. Anthony ML. Surgical treatment of nonmelanoma skin cancer. AORN J 2000; 71:552-8, 560.
8. Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 2000;105:2544-51.
9. Jemec GB, Holm EA. Nonmelanoma skin cancer in organ transplant patients. Transplantation 2003;75:253-7.
10. Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg 1984;73:492-7.
11. Needham, R. C. In: Emmet A, O'Rourke M, editors. Malignant skin tumours. New York: Churchill Livingston; 1982. p. 170-1.
12. Hacker SM, Browder JF, Ramos-Caro FA. Basal cell carcinoma. Choosing the best method of treatment for a particular lesion. Postgrad. Med 1993;93:101-8, 111.
13. Mazurkiewicz M, Peszynski J. Acute radiation reaction and its healing time after skin cancer radiotherapy in elderly patients (in Polish). Pol Merkuriusz Lek 1998;4:199-201.
14. Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst (Bethesda) 1996;88:1848-53.
15. Clurrie, G. In: Emmet A, O'Rourke M, editors. Malignant skin tumours. New York: Churchill Livingston; 1982. p. 176-82.
16. Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981;4:633-49.
17. Dabski K, Helm F. Topical chemotherapy. In: Schwartz RA, editor. Skin cancer: recognition and management. New York: Springer-Verlag; 1998. p. 378-89.
18. Hill BH. Occurrence of squamous carcinoma in hyperkeratoses and Bowenoid lesions treated with 5-fluorouracil. Australas J Dermatol 1970;11:107.
19. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
20. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
21. Weedon D, Chick J. Home treatment of basal cell carcinoma. Med J Aust 1976;1:928.
22. Green AC, Beardmore GL. Home treatment of skin cancer and solar keratoses. Australas J Dermatol 1988;29:127-30.
23. Maynard K, Parsons PG. Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype. Cancer Res 1986;46:5009-13.
24. Cavanagh LL, Halliday GM. Dendritic epidermal T cells in ultraviolet-irradiated skin enhance skin tumor growth by inhibiting CD4+ T-cell-mediated immunity. Cancer Res 1996;56:2607-15.
25. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (Bethesda) 1990;82:1107-12.
26. Cunarro J, Weiner MW. Mechanism of action of agents which uncouple oxidative phosphorylation: direct correlation between proton-carrying and respiratory-releasing properties using rat liver mitochondria. Biochim Biophys Acta 1975; 387:234-40.
27. Minamikawa T, Williams DA, Bowser DN, Nagley P. Mitochondrial permeability transition and swelling can occur reversibly without inducing cell death in intact human cells. Exp Cell Res 1999;246:26-37.
28. Smiley ST, Reers M, Mottola-Hartshorn C, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991;88:3671-5.
29. Walsh GM, Dewson G, Wardlaw AJ, Levi-Schaffer F, Moqbel R. A comparative study of different methods for the assessment of apoptosis and necrosis in human eosinophils. J Immunol Methods 1998;217:153-63.
30. Brenner C, Le Bras M, Kroemer G. Insights into the mitochondrial signaling pathway: what lessons for chemotherapy? J. Clin Immunol 2003;23:73-80.
31. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002;21:8786-803.
32. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341(Pt 2):233-49.
33. Nieminen AL. Apoptosis and necrosis in health and disease: role of mitochondria. Int Rev Cytol 2003;224:29-55.
34. Nishimura Y, Lemasters JJ. Glycine blocks opening of a death channel in cultured hepatic sinusoidal endothelial cells during chemical hypoxia. Cell Death Differ 2001;8:850-8.
35. Kim JS, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003;304: 463-70.
36. Gazzaniga S, Bravo A, Goldszmid SR, et al. Inflammatory changes after cryosurgery-induced necrosis in human melanoma xenografted in nude mice. J Investig Dermatol 2001;116:664-71.
37. Fujiwara M, Okamoto M, Ijichi K, et al. Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Arch Virol 1998;143:2003-10.
38. Barry OP, Kazanietz MG. Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 2001;7:1725-44.
39. Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 2001;142:1-96.
40. Kumar S, Bharti A, Mishra NC, et al. Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. J Biol Chem 2001;276:17281-5.
41. Majumder PK, Pandey P, Sun X, et al. Mitochondrial translocation of protein kinase C δ in phorbol ester- induced cytochrome c release and apoptosis. J Biol Chem 2000;275:21793-6.
42. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase Cα in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998;273:25436-42.
43. Cartee L, Kucera GL. Protein kinase C modulation and anticancer drug response. Cancer Invest 2000;18:731-39.
44. Musashi M, Ota S, Shiroshita N. The role of protein kinase C isoforms in cell proliferation and apoptosis. Int J Hematol 2000;72:12-9.
45. Wang QJ, Bhattacharyya D, Garfield S, Nacro K, Marquez VE, Blumberg PM. Differential localization of protein kinase Cδ by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J Biol Chem 1999;274:37233-9.
46. Chida K, Hara T, Hirai T, et al. Disruption of protein kinase Cη results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. Cancer Res 2003;63:2404-8.
47. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-70.
48. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22:3152-61.
49. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.